Add Company
Join Now

PreludeDx Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • PreludeDx's estimated annual revenue is currently $14.3M per year.(i)
  • PreludeDx's estimated revenue per employee is $155,000

Employee Data

  • PreludeDx has 92 Employees.(i)
  • PreludeDx grew their employee count by 35% last year.

PreludeDx's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
CSOReveal Email/Phone
3
Chief PathologyReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
6
VP, Business DevelopmentReveal Email/Phone
7
VP Scientific AffairsReveal Email/Phone
8
VP, Revenue CycleReveal Email/Phone
9
VP Strategic Marketing and Business DevelopmentReveal Email/Phone
10
VP, International SalesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is PreludeDx?

PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?

keywords:N/A

N/A

Total Funding

92

Number of Employees

$14.3M

Revenue (est)

35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.2M9223%N/A
#2
N/A9211%N/A
#3
$9.2M92-4%N/A
#4
$24.8M9224%N/A
#5
$32.5M923%N/A